Non-NEPA Federal Register Notices (HHS/FDA/IHS/NIH)

Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments; Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability

This document is not a NEPA filing. It is an FDA notice of availability published in the Federal Register on November 18, 2025, announcing a final guidance document (Guidance 3 of 4) in the Patient-Focused Drug Development series, covering how stakeholders can select, develop, or modify clinical outcome assessments for use in medical product development and regulatory decision-making. No environmental review, federal land action, or NEPA process is involved. No impacts, mitigations, alternatives, or comment periods apply.

Request for Public Comment: 60 Day Notice for Extension of Fast Track Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery: Indian Health Service Customer Service Satisfaction and Similar Surveys

This Federal Register page (Vol. 89, No. 246, December 23, 2024) contains no NEPA documents. The notices present are: an FDA/CDER internal reorganization notice, an HRSA Advisory Council on Blood Stem Cell Transplantation public meeting notice, an Indian Health Service Paperwork Reduction Act comment solicitation, and several NIH National Institute on Aging closed grant-review meeting notices. None of these are NEPA actions, EIS documents, NOIs, NOAs, EAs, or RODs. No environmental impact analysis, project siting, or NEPA review is present.